[Induction of anti-cancer cells and systemic immune response in hepatocellular carcinoma by OK-432].
We examined whether anti-cancer cells are induced in vivo in hepatocellular carcinoma (HCC) by OK-432. Ten patients with HCC were randomly divided into two groups. The group I patient (n = 5) served as the control. In group II (n = 5), OK-432 was preoperatively administered via the hepatic artery. Tumor infiltrating lymphocytes (TILs) were collected from resected tumors. Cytotoxicity of TILs against K562 cells and Raji cells was studied with phenotypic analysis by flow cytometry. Freshly isolated TILs, whether or not treated with OK-432, showed low cytotoxicity. When TILs were co-cultured with recombinant interleukin-2 (rIL-2), the cytotoxicity was significantly activated in the OK-432 treated group, whereas untreated TILs showed no activation. The natural killer (NK) activity and the lymphokine-activated killer (LAK) activity were depressed in group I after hepatic resection, but patients in group II had no depression. Our data indicate that LAK precursor cells are induced in TILs and the prevention of post-operative immune suppression is made possible by OK-432.
Aramaki
M
M
Dept. of Surgery I, Oita Medical University.
Nakashima
K
K
Sasaki
A
A
Shimoda
K
K
Yoshida
T
T
Kim
Y I
YI
Kitano
S
S
Kobayashi
M
M
D006528:Carcinoma, Hepatocellular / Q000276:immunology* / Q000628:therapy; D003602:Cytotoxicity, Immunologic; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D007459:Iodized Oil / Q000008:administration & dosage; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008113:Liver Neoplasms / Q000276:immunology* / Q000628:therapy; D016131:Lymphocyte Subsets / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000008:administration & dosage*
D010844:Picibanil; D007459:Iodized Oil